Related Experiment Video
Updated: Jul 19, 2026

A Rodent Model of The Ross Operation: Syngeneic Pulmonary Artery Graft Implantation in A Systemic Position
Published on: April 1, 2022
Redo aortic valve replacement in children
Kirk R Kanter1, Paul M Kirshbom, Brian E Kogon
1Division of Cardio-Thoracic Surgery, Department of Surgery, Emory University School of Medicine, Atlanta, Georgia 30322, USA. kkanter@emory.edu
Insights
Redo aortic valve replacement (AVR) in children is feasible with acceptable outcomes, though repeat reoperations increase risk. Early referral is crucial to prevent ventricular dysfunction and improve results for pediatric cardiac surgery patients.
Area of Science:
- Pediatric Cardiac Surgery
- Congenital Heart Disease Management
- Cardiovascular Therapeutics
Background:
- A subset of children undergoing aortic valve replacement (AVR) require subsequent valve re-replacement (redo-AVR).
- This study analyzes outcomes from 38 redo-AVRs performed on 30 pediatric patients.
Purpose of the Study:
- To evaluate the safety and efficacy of redo-AVR in a pediatric population.
- To identify factors influencing outcomes in children requiring repeat aortic valve surgery.
Main Methods:
- Retrospective analysis of 38 redo-AVRs in 30 children (age 2 months–20 years).
- Indications included stenosis, regurgitation, endocarditis, thrombosis, and aneurysm.
- Surgical techniques involved prosthesis implantation, often with annulus enlargement (Konno, Manougian procedures).
Main Results:
- Most redo-AVRs used mechanical prostheses; 71% involved annulus enlargement.
- Upsizing the valve prosthesis was common (25 valves, median increase 4 mm).
- Hospital mortality was higher in second or third redo-AVRs; the only death in first redo-AVR patients was in cardiogenic shock.
Conclusions:
- Redo-AVR in children can be achieved with manageable morbidity and mortality.
- Larger valve prostheses can be successfully implanted during redo-AVR.
- Second or third redo-AVRs carry higher risks, underscoring the need for early referral before ventricular dysfunction develops.
Background:
Some children who have had an aortic valve replacement (AVR) will need valve re-replacement (redo-AVR). We analyzed our results with 38 redo-AVRs in 30 children.
Methods:
Thirty children, aged 2 months to 20 years (mean, 11.5 +/- 5.4 years), underwent 38 redo-AVRs 1 month to 14 years (mean, 4.6 +/- 4.5 years) after previous AVR. Seven children had a second redo-AVR and one had a third redo-AVR (his fourth AVR). Reoperation indication was primarily stenosis in 19, regurgitation in 12, endocarditis in 3, valve thrombosis-emboli in 3, and ruptured aortic aneurysm in 1. The initial valve was mechanical in 26, homograft in 7, xenograft in 4, or a Ross procedure in 1. Sixteen patients (42%) had a previous Konno procedure.
Results:
The new valve was mechanical (28), homograft (5), xenograft (4), or a Ross procedure (1). Twenty-five valves were upsized on re-replacement. The median valve size was 23 mm (median size increase 4 mm). Twenty-seven operations (71%) included annulus enlargement (16 redo-Konno, 8 new Konno, and 3 Manougian). Twelve children (32%) had concomitant operations including mitral valve repair-replacement (4) and right ventricular outflow tract procedure (5). Three of the 4 hospital deaths were with second or third time redo-AVR. The only death in patients with first time redo-AVR was a patient in cardiogenic shock at the time of operation.
Conclusions:
Redo-AVR in children can be performed with reasonable morbidity and mortality. A larger prosthesis can often be placed in these children. Second or third time redo-AVR appears to be riskier. Earlier referral before onset of ventricular dysfunction is warranted.
More Related Videos
Related Concept Videos
Aortic Regurgitation III: Medical Management
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
Aortic Regurgitation I: Introduction
Mitral Stenosis III: Medical Management

